ALGS (Aligos Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ALGS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-29 | Margarita Chavez | Director | A | — | — |
| 2026-06-29 | Bridget A Martell | Director | A | — | — |
| 2026-06-29 | Heather Preston | Director | A | — | — |
| 2026-06-29 | Carole Nuechterlein | Director | A | — | — |
| 2026-06-29 | Peter Hirth | Director | A | — | — |
| 2026-06-29 | James Paul Scopa | Director | A | — | — |
| 2026-03-11 | Julian A. Symons | See Remarks | A | — | — |
| 2026-03-11 | Nikhil Aneja | Principal Accounting Officer | A | — | — |
| 2026-03-11 | LAWRENCE BLATT | President and CEO | A | — | — |
| 2026-03-11 | Lesley Ann Calhoun | See Remarks | A | — | — |
| 2025-07-18 | LAWRENCE BLATT | President and CEO | A | — | — |
| 2025-07-18 | Julian A. Symons | See Remarks | A | — | — |
| 2025-07-18 | Lesley Ann Calhoun | See Remarks | A | — | — |
| 2025-06-26 | Margarita Chavez | Director | A | — | — |
| 2025-06-26 | Bridget A Martell | Director | A | — | — |
| 2025-06-26 | Peter Hirth | Director | A | — | — |
| 2025-06-26 | Carole Nuechterlein | Director | A | — | — |
| 2025-06-26 | James Paul Scopa | Director | A | — | — |
| 2025-06-26 | Heather Preston | Director | A | — | — |
| 2025-03-04 | LAWRENCE BLATT | President and CEO | A | — | — |
| 2025-03-04 | Lesley Ann Calhoun | See Remarks | A | — | — |
| 2025-03-04 | Julian A. Symons | See Remarks | A | — | — |
| 2024-10-10 | Hardean Achneck | Chief Medical Officer | A | — | — |
| 2024-09-06 | Julian A. Symons | See Remarks | A | — | — |
| 2024-09-06 | LAWRENCE BLATT | Chief Executive Officer | A | — | — |
| 2024-09-06 | Lesley Ann Calhoun | — | A | — | — |
| 2024-08-09 | Margarita Chavez | Director | A | — | — |
| 2024-08-09 | Heather Preston | Director | A | — | — |
| 2024-06-28 | James Paul Scopa | Director | A | — | — |
| 2024-06-28 | Peter Hirth | Director | A | — | — |
| 2024-06-28 | Bridget A Martell | Director | A | — | — |
| 2024-06-28 | Carole Nuechterlein | Director | A | — | — |
| 2024-03-04 | Julian A. Symons | See Remarks | A | — | — |
| 2024-03-04 | Matthew W. McClure | Chief Medical Officer | A | — | — |
| 2024-03-04 | LAWRENCE BLATT | Chief Executive Officer | A | — | — |
| 2024-03-04 | Lesley Ann Calhoun | — | A | — | — |
| 2024-02-28 | Peter Hirth | Director | MIXED | — | — |
| 2024-02-28 | Carole Nuechterlein | Director | MIXED | — | — |
| 2024-02-28 | Jack Nielsen | Director | MIXED | — | — |
| 2024-02-28 | Julian A. Symons | See Remarks | MIXED | — | — |
| 2024-02-28 | Bridget A Martell | Director | MIXED | — | — |
| 2024-02-28 | LAWRENCE BLATT | Chief Executive Officer | MIXED | — | — |
| 2024-02-28 | James Paul Scopa | Director | MIXED | — | — |
| 2024-02-28 | Lesley Ann Calhoun | — | MIXED | — | — |
| 2024-02-28 | Matthew W. McClure | Chief Medical Officer | MIXED | — | — |
| 2023-10-27 | James Paul Scopa | Director | A | — | — |
| 2023-10-27 | LAWRENCE BLATT | Chief Executive Officer | A | — | — |
| 2023-10-27 | Carole Nuechterlein | Director | Buy | — | — |
| 2023-09-12 | LAWRENCE BLATT | Chief Executive Officer | A | — | — |
| 2023-09-12 | Matthew W. McClure | Chief Medical Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 441,038 | — |
| — | 10%+ Owner | 123,694 | — |
| — | 10%+ Owner | 96,583 | — |
| — | 10%+ Owner | 96,373 | — |
| — | President and CEO | 78,440 | — |
| — | Director | 58,495 | — |
| — | 10%+ Owner | 53,402 | — |
| — | President | 41,622 | — |
| — | See Remarks | 15,763 | — |
| — | See Remarks | 15,363 | — |
| — | Director | 7,323 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ALGS quote page; the site-wide leaderboard is on the insider transactions hub.